Viewing Study NCT00319332

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:56 PM
Ignite Modification Date: 2026-04-07 @ 1:22 PM
Study NCT ID: NCT00319332
Status: WITHDRAWN
Last Update Posted: 2015-04-17
First Post: 2006-04-26
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
Sponsor: GlaxoSmithKline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lymphoma, Small Cleaved-Cell, Follicular View
None Lymphoma, Large-Cell, Follicular View
None Lymphoma, Follicular View
None Lymphoma, Non-Hodgkin View
Keywords:

Keywords

Keyword Brief Keyword Text View
None non-Hodgkin's Lymphoma View
None follicular lymphoma View
None BEXXAR View
None ZEVALIN View
None Iodine I 131 Tositumomab View
None Ibritumomab Tiuxetan View
None Follicular, mixed small-cleaved and large-cell View
None Diffuse large cell non-Hodgkin's lymphoma following or concurrent with a … View